Insider Selling: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company’s stock, valued at approximately $342,303. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Neumora Therapeutics Price Performance

NASDAQ NMRA opened at $16.49 on Monday. Neumora Therapeutics, Inc. has a 1 year low of $8.33 and a 1 year high of $21.00. The company has a market capitalization of $2.63 billion and a PE ratio of -6.44. The company has a fifty day moving average of $12.73 and a 200 day moving average of $11.33.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). Research analysts expect that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank lifted its stake in shares of Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares during the period. Quarry LP purchased a new position in Neumora Therapeutics in the second quarter valued at $98,000. SkyOak Wealth LLC purchased a new position in Neumora Therapeutics in the second quarter valued at $147,000. Principal Financial Group Inc. acquired a new position in shares of Neumora Therapeutics in the second quarter worth about $166,000. Finally, Clarius Group LLC purchased a new stake in shares of Neumora Therapeutics during the 3rd quarter worth about $224,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on NMRA. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Friday. Mizuho initiated coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Finally, HC Wainwright began coverage on Neumora Therapeutics in a research report on Tuesday, October 1st. They set a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.83.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.